JPMorgan Chase & Co. Boosts Stake in Kura Oncology, Inc. (NASDAQ:KURA)

JPMorgan Chase & Co. grew its holdings in Kura Oncology, Inc. (NASDAQ:KURA) by 0.8% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 409,241 shares of the company’s stock after purchasing an additional 3,092 shares during the period. JPMorgan Chase & Co. owned approximately 0.53% of Kura Oncology worth $7,997,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. nVerses Capital LLC acquired a new position in Kura Oncology in the third quarter valued at about $25,000. The Manufacturers Life Insurance Company lifted its holdings in shares of Kura Oncology by 5.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,536 shares of the company’s stock worth $793,000 after acquiring an additional 1,976 shares during the last quarter. Hsbc Holdings PLC boosted its position in shares of Kura Oncology by 13.4% during the 2nd quarter. Hsbc Holdings PLC now owns 18,300 shares of the company’s stock worth $374,000 after purchasing an additional 2,167 shares during the period. Bellevue Group AG grew its stake in shares of Kura Oncology by 36.0% in the third quarter. Bellevue Group AG now owns 13,600 shares of the company’s stock valued at $266,000 after buying an additional 3,600 shares in the last quarter. Finally, HighVista Strategies LLC lifted its stake in Kura Oncology by 26.2% during the 3rd quarter. HighVista Strategies LLC now owns 21,161 shares of the company’s stock worth $413,000 after acquiring an additional 4,397 shares in the last quarter.

Kura Oncology Stock Performance

NASDAQ:KURA opened at $7.26 on Wednesday. Kura Oncology, Inc. has a 12 month low of $6.98 and a 12 month high of $24.17. The company has a debt-to-equity ratio of 0.02, a current ratio of 11.47 and a quick ratio of 11.47. The firm has a market capitalization of $564.57 million, a PE ratio of -3.08 and a beta of 0.81. The business’s fifty day moving average price is $11.14 and its 200 day moving average price is $16.61.

Analyst Ratings Changes

Several research firms have weighed in on KURA. Jefferies Financial Group dropped their target price on Kura Oncology from $32.00 to $28.00 and set a “buy” rating for the company in a research report on Thursday, November 21st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Kura Oncology in a research note on Monday, December 9th. Bank of America decreased their price target on shares of Kura Oncology from $36.00 to $29.00 and set a “buy” rating for the company in a research report on Friday, November 22nd. UBS Group began coverage on Kura Oncology in a research report on Thursday, October 24th. They set a “buy” rating and a $27.00 price objective on the stock. Finally, HC Wainwright lifted their target price on Kura Oncology from $32.00 to $37.00 and gave the company a “buy” rating in a report on Thursday, November 21st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $27.38.

Kura Oncology Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.